Manufacturing investment demonstrates the expected scale and permanence of the market. publication date:31 July 2026 Source or person: Eli Lilly and National Resilience The investment will expand US manufacturing capacity for the KwikPen devices used to deliver Lilly’s injectable diabetes and obesity medicines, showing that manufacturers expect sustained mass-market demand.
Grab The link : https://www.biospace.com/glp-1